FDA 483 - Janssen Pharmaceutica, N.V. - September 05, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Janssen Pharmaceutica N.V., a biopharmaceutical facility in Beerse, Antwerpen, Belgium, revealed significant data integrity and reporting deficiencies. The firm failed to accurately convey all tested particle size distribution (PSD) samples and data, including rejected samples and incorrect values, in method validation and study reports. Additionally, not all in vitro release testing (IVRT) incidents and repeated tests were properly documented and conveyed in reports.
ID · 6c8e1b3c-df77-49af-9a7b-08fc5cf52d66